Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in... | April 26, 2023
Therapeutics Inc Ligand Pharmaceuticals Incorporated Prnewswire Viking Therapeutics Inc Exchange Commission Additional Data Announcements Expected Data Expected
Source: marketscreener.com